Zeke Capital Advisors’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History

Zeke Capital Advisors’s Portfolio BCTXW Stock Details BCTXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$92.7K	Hold	45,000	–	–	0.01%	457
2022 Q3	$129K	Hold	45,000	–	–	0.01%	446
2022 Q2	$117K	Hold	45,000	–	–	0.01%	457
2022 Q1	$234K	Hold	45,000	–	–	0.01%	440
2021 Q4	$211K	Hold	45,000	–	–	0.01%	276
2021 Q3	$214K	Hold	45,000	–	–	0.01%	270
2021 Q2	$81K	Hold	45,000	–	–	0.01%	324
2021 Q1	$48K	Buy	+45,000	New	+$44.1K	﹤0.01%	299

Other funds holding BCTXW

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

KJHP

K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return

RAM

Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Zeke Capital Advisors's BCTXW Position: Q4 2022 in Review

Zeke Capital Advisors held its BriaCell Therapeutics Corp Warrant (BCTXW) position steady in Q4 2022 at 45,000 shares worth $92.7K. The position accounts for 0.01% of the portfolio, ranked #457.

Zeke Capital Advisors first reported a position in BCTXW in Q1 2021 and has held it in 8 quarters since. The position peaked at $234K in Q1 2022. 8 funds tracked by Wall St. Rank hold BCTXW as of Q4 2022.

Zeke Capital Advisors held 45,000 shares of BriaCell Therapeutics Corp Warrant worth $92.7K as of Q4 2022.
Zeke Capital Advisors left its BriaCell Therapeutics Corp Warrant share count unchanged in Q4 2022.
BriaCell Therapeutics Corp Warrant made up 0.01% of Zeke Capital Advisors's portfolio in Q4 2022, its #457 holding.
Zeke Capital Advisors first reported a position in BriaCell Therapeutics Corp Warrant in Q1 2021 and has held it in 8 quarters since.
Zeke Capital Advisors's BriaCell Therapeutics Corp Warrant position peaked at $234K in Q1 2022.
8 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q4 2022.

Based on Zeke Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.